| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| WEREWOLF THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.12.25 | H.C. Wainwright senkt Kursziel für Werewolf Therapeutics nach Pipeline-Update drastisch | 16 | Investing.com Deutsch | ||
| 19.12.25 | H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update | 3 | Investing.com | ||
| 18.12.25 | Werewolf Therapeutics, Inc. - 8-K, Current Report | 13 | SEC Filings | ||
| 04.11.25 | Werewolf Therapeutics reports Q3 results | 10 | Seeking Alpha | ||
| 04.11.25 | Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.11.25 | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.10.25 | Werewolf Therapeutics Says FDA Grants Fast Track For WTX-124 In Advanced Melanoma Treatment | 4 | RTTNews | ||
| 08.10.25 | Werewolf Therapeutics receives FDA Fast Track for melanoma therapy | 3 | Investing.com | ||
| 08.10.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | 342 | GlobeNewswire (Europe) | Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:... ► Artikel lesen | |
| 06.10.25 | Todesfall im Verwaltungsrat: Werewolf Therapeutics erfüllt NASDAQ-Regeln für Prüfungsausschuss nicht mehr | 8 | Investing.com Deutsch | ||
| 06.10.25 | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.10.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.08.25 | Citizens JMP lowers Werewolf Therapeutics stock price target to $3 from $4 | 5 | Investing.com | ||
| 14.08.25 | Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 14.08.25 | Werewolf Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 08.05.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 392 | GlobeNewswire (Europe) | - WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking... ► Artikel lesen | |
| 17.04.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer | 486 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of... ► Artikel lesen | |
| 11.03.25 | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 500 | GlobeNewswire (Europe) | - Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| EVOTEC | 6,148 | +0,79 % | SDAX: Evotec-Aktie schießt zweistellig nach oben | Eine Kaufempfehlung von Berenberg entfacht neuen Optimismus bei Evotec und katapultiert die Biotech-Aktie an die Indexspitze. Die Aktie der Evotec hat am Dienstagmittag ein Kursfeuerwerk gezündet und... ► Artikel lesen | |
| BB BIOTECH | 50,60 | -0,78 % | BB Biotech: Gewinnsprung 2025 und höhere Dividende geplant | Die BB Biotech AG hat für das Geschäftsjahr 2025 vorläufig einen Nettogewinn von 578 Millionen CHF ausgewiesen, nach 76 Millionen CHF im Vorjahr. Die Ergebnisse der Biotech-Beteiligungsgesellschaft... ► Artikel lesen | |
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| BIOGEN | 164,25 | +3,79 % | Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,387 | +2,38 % | BioNxt sichert sich innovative Chaperon-Technologie zur Verbesserung der oralen Dünnfilm-Wirkstoffverabreichung | VANCOUVER, BC / ACCESS Newswire /
5. Februar 2026 - BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT), ein biowissenschaftliches
Innovationsunternehmen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| BAVARIAN NORDIC | 26,050 | +0,19 % | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program |